淋巴细胞与单核细胞比值与食管鳞癌预后的关系。
Lymphocyte-to-monocyte ratio in esophageal squamous cell carcinoma prognosis.
机构信息
Department of Breast surgery, Thyroid surgery, Pancreatic surgery, Huangshi Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, No.141, Tianjin Road, Huangshi, Hubei, China.
Department of Breast surgery, Thyroid surgery, Pancreatic surgery, Huangshi Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, No.141, Tianjin Road, Huangshi, Hubei, China.
出版信息
Clin Chim Acta. 2018 Nov;486:44-48. doi: 10.1016/j.cca.2018.07.029. Epub 2018 Jul 17.
INTRODUCTION
Recently, the prognostic value of the lymphocyte-to-monocyte ratio (LMR) has been widely evaluated in multiple malignancies. However, its prognostic value in patients with esophageal squamous cell carcinoma (ESCC) remains controversial. Herein, we perform a meta-analysis to assess the prognostic value of the preoperative LMR in ESCC.
METHODS
Relevant studies were systematically retrieved from the online Cochrane, MEDLINE, and EMBASE databases published until March 2018. Data from studies reporting a hazard ratio (HR) and 95% confidence interval (CI) were weighted by generic inverse-variance and pooled in either fixed-effects models or random effects meta-analysis. Seven eligible studies involving 1701 patients were analyzed in this meta-analysis.
RESULTS
The synthesized analysis showed that patients with low LMR had a significantly shorter overall survival (OS) (HR: 0.67, 95% CI: 0.58-0.78, p < 0.001) and disease-free survival (DFS)/progression-free survival (PFS) (HR: 0.67, 95% CI: 0.50-0.92, p = 0.01). Additionally, low LMR was correlated with TNM stage (III-IV vs. I-II; HR = 1.94, 95% CI: 1.16-3.22, P = 0.01) and tumor recurrence (yes vs. no; HR = 1.71, 95% CI: 1.06-2.77, P = 0.03).
CONCLUSION
Low LMR was associated with advanced clinicopathological features and poor prognosis as a predicative biomarker in patients with ESCC.
简介
最近，淋巴细胞与单核细胞比值（LMR）的预后价值已在多种恶性肿瘤中得到广泛评估。然而，其在食管鳞状细胞癌（ESCC）患者中的预后价值仍存在争议。在此，我们进行了一项荟萃分析，以评估术前 LMR 在 ESCC 中的预后价值。
方法
系统地从在线 Cochrane、MEDLINE 和 EMBASE 数据库中检索相关研究，检索时间截至 2018 年 3 月。对报告风险比（HR）和 95%置信区间（CI）的研究数据进行加权处理，采用固定效应模型或随机效应荟萃分析进行汇总分析。本荟萃分析共纳入 7 项研究，共计 1701 例患者。
结果
综合分析显示，LMR 较低的患者总生存期（OS）（HR：0.67，95%CI：0.58-0.78，p<0.001）和无病生存期（DFS）/无进展生存期（PFS）（HR：0.67，95%CI：0.50-0.92，p=0.01）明显更短。此外，LMR 水平与 TNM 分期（III-IV 期 vs. I-II 期；HR=1.94，95%CI：1.16-3.22，p=0.01）和肿瘤复发（是 vs. 否；HR=1.71，95%CI：1.06-2.77，p=0.03）显著相关。
结论
LMR 水平较低与 ESCC 患者的临床病理特征较晚和预后不良相关，可作为预测标志物。
Zotero 插件